Healthy Subjects
Conditions
Keywords
Healthy, Metabolism, Drug-Drug Interactions
Brief summary
This study will be a single center, open-label, drug-drug interaction study in healthy male and female subjects. The study will consist of 2 parts. In Part A, the effects of steady-state dosing of a strong CYP3A inhibitor (itraconazole) or inducer (rifampin) on the pharmacokinetics of E2006 and metabolites will be assessed. Approximately 30 subjects will be sequentially assigned to 1 of 2 treatment groups to receive itraconazole or rifampin in equal numbers (approximately 15 subjects per group). The itraconazole treatment group will be fully enrolled before enrollment is initiated for the rifampin treatment group. In Part B, the effects of steady-state dosing of E2006 on the pharmacokinetics of midazolam, a substrate of CYP3A, plus bupropion, a substrate of CYP2B6, will be assessed in approximately 24 subjects. The 2 study parts can be conducted in parallel.
Interventions
Sponsors
Eisai Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects must meet all of the following criteria to be included in this study: 1. Healthy males or females, ages 18 to 55 years 2. Body mass index greater than 18 and less than or equal to 32 kg/m2 at Screening 3. All females must be of nonchildbearing potential 4. Males who are not abstinent or have undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use, a highly effective method of contraception 5. Are willing and able to comply with all aspects of the protocol 6. Provide written informed consent
Exclusion criteria
Subjects who meet any of the following criteria will be excluded from this study: 1. Any subject that has a known history of malaria or has traveled to a country with known malarial risk (ie, is designated as high or moderate risk country according to the list available at http://www.cdc.gov/malaria) within the last year 2. Subjects with a history of bowel resection, any malabsorptive disorder, severe gastroparesis, or any gastrointestinal procedure for the purpose of weight loss (including LAP-BANDTM), which would slow gastric emptying and potentially affect PK profiles of E2006 3. Subjects with a known history of clinically significant drug or food allergies 4. Subjects who experienced a weight loss or gain of greater than 10% between Screening and prior to dosing 5. Subjects who had a clinically significant illness that required medical treatment within 8 weeks or a clinically significant infection within 4 weeks of dosing 6. Subjects with any clinically abnormal symptom or organ impairment found in medical history, symptoms or signs, vital sign measurements, electrocardiogram (ECG) findings, or laboratory test results that require medical treatment found in medical history or at screening and baseline 7. Subjects known to be positive for human immunodeficiency virus, or subjects who have positive hepatitis B or hepatitis C screening test results 8. Subjects who have a history of drug or alcohol dependency or abuse (as defined by The Diagnostic and Statistical Manual of Mental Disorders V criteria) within approximately 2 years prior to Screening, or who have a positive urine drug test results at Screening or Baseline 9. Subjects who received blood products within 4 weeks, donated blood within 8 weeks, or donated plasma within 1 week of dosing 10. Subjects who used hormonal replacement therapy within 3 months prior to dosing 11. Subjects who used any drugs, over-the-counter (OTC) medications, nutritional supplements (eg, products containing St John's wort), excessive doses of vitamins (in the opinion of the principal investigator), herbal preparations, or foods or beverages known to modulate CYP (eg, CYP3A4) or transporters within 4 weeks prior to dosing, or who are unwilling to abstain from using these during the study 12. Subjects who engaged in intense physical activity within 1 week prior to Baseline (eg, weight training) 13. Subjects who smoke or have used tobacco or nicotine-containing products within 3 months prior to dosing 14. Subjects who habitually consume more than 400-mg caffeine per day 15. Subjects who participated (received investigational product) in another clinical trial less than 1 month (or 5 elimination half-lives of the investigational product) prior to dosing or who are currently enrolled in another clinical trial 16. Subjects with a disease that may influence the outcome of the study, such as psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or subjects who have a congenital abnormality in metabolism, or subjects who have any condition that would make him or her, in the opinion of the investigator, unsuitable for the study or who, in the opinion of the investigator, are not likely to complete the study for any reason Restrictions on concomitant medications, food and beverages: 17. Prescription drugs are prohibited within 4 weeks of dosing and OTC medications within 2 weeks prior to dosing and until the Termination Visit 18. Smoking or use of tobacco or nicotine-containing products is prohibited within 4 weeks prior to dosing and until Termination Visit 19. Intake of caffeinated beverages or food is prohibited 72 hours prior to dosing and throughout the entire study 20. Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters (eg, alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family \[eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard\] and charbroiled meats) is prohibited within 2 weeks prior to dosing until the Termination Visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): AUC(0-t) | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Area under the concentration-time curve from zero time to time of last quantifiable concentration |
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): AUC(0-inf) | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Area under the concentration-time curve from zero time extrapolated to infinite time |
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): Cmax | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Maximum observed concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): tmax | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Time at which the highest drug concentration occurs |
| Pharmacokinetics of E2006: AUC(0-8h) | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Area under the concentration-time curve from time zero time to 8 hours after dosing (E2006 only) |
| Pharmacokinetics of E2006: AUC(0-24h) | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Area under the concentration-time curve from time zero time to 24 hours after dosing (E2006 only) |
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): AUC(0-72h) | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Area under the concentration-time curve from zero time to time 72 hours after dosing |
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): t1/2 | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Terminal elimination phase half-life |
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): CL/F | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Apparent total clearance after extravascular administration |
| Pharmacokinetics of E2006 and its major metabolites, M4, M9, and M10 (Part A), and midazolam, bupropion, and the hydroxylated metabolite of bupropion (Part B): AUC(0-inf), metabolite ratio | Approximately 56 Days for Part A; Approximately 42 Days for Part B | Ratio of S,S-hydroxybupropion to S-buproprion |
Countries
United States
Outcome results
None listed